to ever XXXX, Thanks, quarter In And of in overall the quarter the the third in fact, well. Rich. history the best continued we've perform recorded we of very company.
we incredible very pushing the of amazing that due teams it's obviously not and amazing all forward. we're about our us product, and And we have the to capabilities only so genome effort with mapping think that the into excited have but that, optical put
for total same develop is and period quarter great in execution, in versus up laboratory-developed was based including revenue customers the million, obtaining many accreditation had We which areas XXX% So on seeing XXXX. of the optical tests. Saphyr-based performance mapping $X.X laboratory-developed genome tests for
as of such various As samples, and And include genome to weight allows from in ultra-high and well prenatal to molecular as apply analysis. DNA prenatal users this us our our to isolation applications expanding protocols CVS. amniocytes for optical menu mapping
we've preparing General President Global President I is Justin North welcome Sales I our Vice to continued Director; and folks our that Customer the scale who Alex growth Stephanie these that Hertsenberg, welcome, Soheil Lineagen made, believe who multiple additional progress Development; Vice industries. Shams, on as President from Bob is the Lettmann, who board is Bionano. then have expand only are Marketing; and Officer these drive our commercially. Experience; VP we Bionano Strategic what least, we've business certainly, them business; and Product who Chief we're to many out to Leighton, the Hernandez, previously of Helm, we incredible who Global to today, announced Sales us. to to want the of not of American join across us Corporate of board not is for Informatics to will want who Amanda build them but Manager the Now Vice and and of President but And is Vice opportunity BioDiscovery. on path of I locations. just the Marketing. was Hoyle, that not And now to of amazing And companies they the because very have think Global who excited people choosing on reflects we the Amanda want come across geographic and is last commercial we team, And new and Officer we're doing front Chief Executive is the And to welcome is our in Training out we And
key to I growth commercial be about organization, Saphyr the system talk want a XXXX. shipments. XX going key the going to rounding installations the little systems the that's Saphyr installed And out and to of the really forward. so had a people installations across we're and development We and September total quarter base bit Saphyr XXX base to of brought We for the during record quarter. in shipped utilization. as Saphyr XX, Saphyrs installed and quarter areas installed
quarter shipped by You reach exceed just to the XXX that systems XX XXXX that to is Saphyr and in consumable believe worldwide the the end of that of in one that even flow goal unit period And ever. during now on cells goal the cells were the can This flow XXXX. quarter. nanochannel mind that same of track genome. installed in in keep We highest And compare we're third we've we flow our shipped is last or the cell number X,XXX XX systems any please array the quarter. for systems were sold sold human
genome to field are flow cells sold that so the leads and mapping of support to data the of awareness being And optical its more proposition into increased and more more utilization utility. value
X,XXX million flow third the represents XXX% the growth period So same of cells quarter XXXX. over
ending XX, that lab, XXXX, to a during and the XXX was same XX quarter year samples. services ago, our September the compare we in analyzed Finally, which period samples we can
coming projects are about new time. learn in samples And the connection happening analysis genome field, with certainly in new so but a for for numbers these coming Saphyr oftentimes are of adoption, first optical in customers the that to that mapping either the potentially are
being know when that's we analyzed, that in awareness going that see capability. to So of genome growth into turn its we are more and optical mapping samples
leading exciting an indicator. that's so And
and making faster to optical we've with Regarding innovation, effective easier, operate. continued mapping Saphyr genome to improve cost more it
incredible And anticipate samples. cultures our to the DNA from and weight We data assays both These BioDiscovery have quarter, be to and prenatal capabilities released analysis going Nexus was which And we They assays build are prototype that next-generation in that key on the genome and software, recently. we've ultra-high CVS offering. we develop and capabilities track optical of a that completing hit of used our markets new first could and and year. the fresh the support expand course, to molecular is to NxClinical cryopreserve we this for by system that and This project platform can for added have Number of isolation updated our Saphyr amniocytes expands Copy the goal end for applications so a also data cells. of capabilities that mapping. interpretation. require serve And we been
authors Regarding optical largest announced Journal very found. than pleased of of in and utility, which to study, demonstrated They've standard published that accurately Molecular the in XXX scope publication the study mapping of its reproducibly that data that optical the rare data mapping we Southern for incredible of the FSHD. the the validate gold Diagnostics see blot. -- we the provided clinical In disease, current more the proliferation of muscle research a analyzed, that was genome more and date to outlined patients in quickly, method genome and outcomes were were
these would the of are to in adopt and efficient high as going biotech support economic mapping for that protocols being and diseases alternative that of that's traditional reimbursement drugs where developed, And require adopting rationale the believe have And rare we analysis FSHD. interest for also And future more it from and support value findings we the analysis note the genome often also pharma so methods, FSHD really that to workflow. those from payers. labs seek underscore optical the and an for third-party applications
biopsy. Sequencing improve is liquid an and technologies adopted this We an and publication for NuProbe diagnostics Quantitative R&D Amplification to leader, advancement. Displacement Saphyr efforts Amplicon So Global, health be important announced a Blocker and and effort is molecular that into reproductive an integrated which their to important
we so for and an this us, drive utilization. is applications important new that to and And expect adoption
meeting, have largest It optical Consortium year. at Saphyr We applications held August tumor our of constitutional to of Cancer was highlighting was of a or postnatal and meeting, Society held annual with And of which The and hematologic others. at of by significant which presented areas, including and globally. meeting, in mapping genetics Genetics, another research posters solid benefits customers pre- presence, genome date, Bionano, in over was late clinical conception, malignancies, for participants Genomics Human European featured products variety of event attendance the in August. the importantly presentations XX this XX analysis, in the XXX talks and the the ESHG customers
mapping in QX. XX Now XXX turning been year-to-date, There to optical includes publications publications. have which genome
samples assays addition samples forward. disorders. data And projects emphasize our for has that received would I processed believe also In our quarter that the customers the to of we to the our in business those good neurodevelopmental for that going in will had put pediatric a lead of hands suite Lineagen across quarter, lab publications
diagnostic with financial statements. service those and for revenues so in other our are included revenue all And services
Alka are a like Those to standard cytogenetic demonstrate are conducted as So of Dr. Medical of to mapping as provide path being to the them part now studies have adopted of that the update care. on led our traditional methods Officer. by genome optical studies I'd on pivotal being to alternative utility Chaubey, an an Chief
these analysis, for and So well. and leukemias span going tumor growth postnatal major and including studies these solid X Recruitment studies analysis. in lymphomas, hematologic genetic malignancies markets is us, pre-
have key each sites as and investigators leaders important principal opinion endpoint. We across study
was of been XXX Human reached that over For Society the XXX be of including authors it of incrementally also ESHG, and of of the out enrolled at and we first X,XXX Genetics, impressive, samples. cases. postnatal valuable poster those to otherwise completed to a and have leveraged very resolve fact, And the which XXX describing the the identifying that study information the and concordance, recent unsolved in of performance study, we meeting one that presented can receive the XXX% across the underway longest, has analysis a subjects total approval initial was IRB samples
and For the site -- prenatal, obtained in been data generation begin IRB this progress, recruitment training and has is and quarter. are will beginning
fourth the end and respectively. begin the sites XXXX quarter programs, of approval to begin of contracts the with the XXXX, fourth For the to the hematologic and of and malignancies are studies expect finalizing we by quarter IRB first in quarter,
data to several in standard will to we genome next believe these recommend generated by of as optical will years, part the studies support the societies basis as that Over changes uses set of of be medical a part mapping care. ultimately serve of as guidelines
would for financials. So is over our an I with Chris update, Officer, Stewart, call like the to that who Financial Chris? the Chief of to overview turn
